Innovative Medicines Canada Responds to Release of Patented Medicine Prices Review Board’s (PMPRB) Final Guidelines

Rose Blan

Press release content from Accesswire. The AP news staff was not involved in its creation. https://apnews.com/press-release/accesswire/business-virus-outbreak-medication-pharmaceutical-manufacturing-health-care-industry-16295f48c714e1c1ea49b9845fbed89c Click to copy OTTAWA, ON / ACCESSWIRE / October 23, 2020 / Innovative Medicines Canada (IMC) issued the following statement today in response to the release of PMPRB’s final Guidelines: “For the last five […]

Press release content from Accesswire. The AP news staff was not involved in its creation.

OTTAWA, ON / ACCESSWIRE / October 23, 2020 / Innovative Medicines Canada (IMC) issued the following statement today in response to the release of PMPRB’s final Guidelines:

“For the last five years we have raised concerns about the negative impact PMPRB’s amendments to the Patented Medicines Guidelines and Regulations will have on Canadian patients. The final Guidelines released today do nothing to relieve those concerns.

“If implemented, they will have a negative impact on Canadian patients. Specifically, innovative new medicines will not launch in Canada, depriving patients of potentially life-changing new treatments; we will see further reductions in the number of clinical trials in this country; and our life sciences sector will lose out on critical investments.

“The height of a global public health crisis is the worst possible time to implement regulatory changes that will have such a direct and negative impact on Canadian patients. This is made even worse because the Guidelines released today are the result of an inadequate consultation process that largely ignored the significant concerns raised by industry, patients, researchers and others.

“Fortunately, there is still time to find a better path. Our members remain committed to their offer to work with government on a solution that meets their important public policy objectives, without undermining Canadians’ access to new medicines, or driving away investment.

“In the meantime, we will continue to ask that Health Canada delay the January 01, 2021 implementation of the final PMPRB Guidelines until after the COVID-19 crisis is passed. At this time our collective focus should only be on the discovery, development and delivery of COVID-19 medicines to treat those infected by the virus, and vaccines to halt its spread.”

About Innovative Medicines Canada

Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.

For further information:

Samantha Thompson

Media Relations

Telephone: 613-790-4555

E-mail:

SOURCE: Innovative Medicines Canada

View source version on accesswire.com:

https://www.accesswire.com/611988/Innovative-Medicines-Canada-Responds-to-Release-of-Patented-Medicine-Prices-Review-Boards-PMPRB-Final-Guidelines

Source Article

Next Post

USA TODAY's experts say securing a COVID-19 vaccine in record time could be easy, but distributing it won't be

Science is making incredible progress toward a COVID-19 vaccine, but as approval nears – potentially as early as December – worry has shifted to the complexity of distribution. © Javier Zarracina Vaccine Pannel promo Overall, hopefulness was the theme of USA TODAY’s vaccine panel this month. After five months, the panel’s countdown clock to a widely available […]